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Abstract
Background: The first human mycobacterial susceptibility 
gene was identified amongst four children on the island of 
Malta in 1995. All affected children were homozygous for a 
nonsense mutation at position 395 of the interferon gamma 
receptor 1 (IFNGR1) gene, and all but one died of overwhelming 
mycobacterial infection.
The population of Malta has high rates of infection with 
intracellular pathogens; leishmania, brucellosis and tuberculosis 
are all endemic, while leprosy, which was previously endemic, 
has only recently been eradicated. We hypothesised that 
heterozygous carriers of the IFNGR1 gene mutation, while 
resistant to infection with poorly pathogenic organisms, may 
have increased susceptibility to infection with more virulent 
pathogens.
Methodology and Result: Screening patients with a past 
history of intracellular infection and healthy newborns for the 
presence of the IFNGR1 A->C395 mutation, using sequence 
specific primer PCR, did not identify any carriers of the 
mutation. 
Conclusion: These results suggest that the IFNGR1 mutation 
is unlikely to be of public health significance on Malta.
Introduction
The identification of the first human mycobacterial 
susceptibility gene in 1995 provided a major breakthrough 
in our understanding of the mechanism of mycobacterial 
infection.1,2 In particular, it highlighted the critical role of the 
interleukin–12/interferon gamma (IL-12/IFNγ) pathway in the 
control of intracellular infection.3 The study of patients with 
genetic mutations that selectively increase susceptibility to 
infection with mycobacteria, and, less commonly, salmonella 
has dramatically increased our understanding of the mechanism 
of immunity to mycobacteria. Parental consanguinity and 
familial forms are frequently observed leading to the description 
of the syndrome Mendelian Susceptibility to Mycobacterial 
Disease (MSMD - MIM 209950). The causal mutations of 
MSMD have been found in five different susceptibility genes: 
Interferon gamma receptor (IFNγ R1) and IFNγ R2, encoding 
the two chains of the receptor for IFNγ; IL-12B, encoding the 
p40 subunit of IL-12; IL12Rβ1, encoding the β1 chain of the 
receptor for IL-12; and the signal transducer and activator of 
transcription-1 (STAT1), encoding an essential transducer of 
IFNγ-mediated signaling (Figure 1). The inheritance is most 
often autosomal recessive, but X-linked recessive has been 
described in one family4 and autosomal dominant inheritance 
has been reported in several other families.5,6 In addition the 
defects can be partial or complete, leading to at least ten different 
disorders. Complete defects cause more severe disease than 
partial defects and there is a spectrum of severity such that 
children with complete IFNγ-R deficiencies present with the 
most profound manifestation of the syndrome.
Four children, all of whom came from a small fishing town 
on the south east coast of Malta, presented with disseminated 
infection from poorly pathogenic mycobacteria. In addition, one 
child also developed a prolonged episode of salmonellosis. Three 
of the four children were known to be related: two were brothers, 
whose parents were second cousins and who were the fourth 
cousins of a third child. The fourth child was not knowingly 
*corresponding author
Malta Medical Journal    Volume 24   Issue 02   2012 17
related to the others but it was likely that all the children had 
inherited the same recessive mutation from a common ancestor. 
A mutation in the interferon gamma receptor 1 (IFNGR1) gene 
was identified and the children were found to be homozygous for 
the defect,1 a nonsense mutation at nucleotide 395 of the IFNGR1 
gene (A>C 395). The resultant stop codon produced a truncated 
protein lacking the transmembrane and cytoplasmic domain, 
with complete abrogation of receptor expression on cell surfaces 
and a functional defect in the up-regulation of tumour necrosis 
alpha (TNF-alpha) by macrophages in response to IFNγ.7
Since this initial description, no further cases of IFNGR1 
deficiency have been identified in Malta. However, the frequency 
of carriers of the mutation in the Maltese population remains 
unknown. While the heterozygous parents and siblings of the 
affected Maltese children remained healthy, functional studies 
showed them to have defective in vitro production of TNFα in 
response to lipopolysaccharide (LPS) and IFNγ, together with 
defective T-cell proliferative responses and defective IFNγ 
production in response to mycobacterial antigens.8,9 This raised 
the intriguing question of whether heterozygous carriers of the 
defect, while resistant to poorly pathogenic mycobacteria, would 
have an increased susceptibility to infection with more virulent 
intracellular organisms.
The population of Malta, in common with other countries 
bordering the Mediterranean littoral, has relatively high rates 
of infection with intracellular organisms. Leishmaniasis, 
brucellosis and tuberculosis (TB) are all endemic to the island 
while leprosy, which was previously endemic, has only recently 
been eradicated. Both visceral (VL) and cutaneous leishmaniasis 
(CL) occur in Malta and are caused by Leishmania infantum, 
a member of the L. donovani complex. Since 1946, notification 
of any human cases of either CL or VL has been compulsory 
with a total of 1246 VL and 36 CL cases notified by 1999 
(Department of Health, Government of Malta). Since then, the 
annual incidence has declined steadily, with only 1.07 cases (range 
0-2.06) /100,000 population since 1995-2007.10
Leprosy was found in Malta for centuries and, at its peak 
in the late nineteenth century, a leprosarium was built which 
still exists. The first Maltese leprosy eradication programme 
began in June 1972 and, at the outset, a total of 261 cases were 
recorded, two thirds of whom had lepromatous leprosy (LL).11 LL 
is characterised by multibacillary disease, a high number of skin 
lesions, chronicity and long-term complications,12 consistent 
with an inability to mount an effective type 1 cytokine response 
and low IFNγ production. 
Brucellosis, a chronic granulomatous disease that may 
have an insidious or acute onset, is endemic in Mediterranean 
countries and only Brucella melitensis (B. melitensis) biovar 
1 has been isolated on the Maltese islands.13 Infection is 
acquired primarily by ingestion of contaminated raw milk or 
unpasteurised cheese. Human brucellosis cases number about 
1 to 20 per year in Malta, with the highest number occurring in 
the 25 to 34 year age group.13 While eradication of brucellosis 
from the Maltese islands is a foreseeable goal, this has not been 
achieved to-date.
The number of TB notifications in Malta over the period 
1990-2008 was small, averaging 5.53 (1.5-12.3) cases per 
100,000 per year (Personal communication, Dr David Pace, 
Paediatric Infectious Diseases Clinic, Mater Dei Hospital, 
Malta). 
Given the high prevalence of intracellular infections in 
Malta, and the discovery of a cluster of families carrying a defect 
in the IFNGR1 gene, we postulated that patients from the island 
with a past history of infection with brucella, leishmania, leprosy 
and TB could have a higher rate of carriage of the IFNGR1 
gene A>C 395 mutation compared with healthy controls. We 
therefore screened for the frequency of this mutation in healthy 
Maltese newborns and in a cohort of patients with a past history 
of intracellular infection using sequence specific primer PCR 
(SSP-PCR).14-16
Materials and methods
In the absence of any data on the expected prevalence of the 
IFNGR1 gene (A>C 395) mutation in the Maltese population, 
we assumed a prevalence of the abnormal allele in the control 
population of 0.5%, and of 5% in patients with a history of 
intracellular disease. A total sample size of 414 controls and 
138 patients was therefore required for a study with a 95% CI 
at 80% power.
Figure 1: Interaction between the macrophage, 
T-cell and mycobacteria
Legend: The stars represent the sites of the main single gene defects in 
Mendelian. Susceptibility to Mycobacterial disease. Six single gene defects 
at 5 main sites have been shown to be essential for maintaining the integrity 
of the interleukin-12/interferon gamma (IL-12/IFNγ) pathway in the control 
of intracellular infection.3 These include defects in the IFNGR1, IFNGR2, 
IL12RB1,IL12B and STAT1 genes. Further description of this pathway is 
beyond the scope of this paper but is well described in the literature.
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Approval to complete the study was obtained from the ethics 
committees of St Luke’s Hospital, Gwardamangia, and St Mary’s 
Hospital, London. 
Patients with a past history of brucellosis, leishmaniasis, 
leprosy or TB were identified from the Malta public health 
records available up to 1998 when the study was conducted. 
These individuals were contacted by post and invited to donate 
a sample of blood for DNA extraction when written informed 
consent was also obtained. Information regarding the disease 
type (extra-pulmonary TB vs pulmonary TB, lepromatous vs 
tuberculoid leprosy and VL vs CL) was obtained from public 
health records. No retrospective review of patient notes was 
carried out. Patients were not screened for HIV infection but at 
the time of completing this study the HIV seroprevalence rate 
was <0.1% amongst adults. Cord blood samples taken for routine 
neonatal screening from healthy newborn infants were obtained 
from the Malta Biobank at the University of Malta. DNA was 
extracted from whole blood by salting out, re-suspended in TE 
buffer and stored at -20°C prior to use.17
A rapid and simple, one-step genotyping method was used 
to test for the presence of the A>C 395 mutation in the IFNGR1 
gene, using sequence specific primers (PCR-SSP) capable of 
distinguishing between the wild type and mutant sequence.14-16 
Primers were obtained from Cruachem (Glasgow) and designed 
by Dr Sarah Marshall, Tissue Typing Laboratory, Regional 
Transplant Centre, Churchill Hospital, Oxford, UK. 
Primer sequences were as follows: 
•   common (sense) primer 5´-CAGAATGGATTGATGCCTGC-3´ 
•   mutant (anti-sense) primer 5´-GGCATACAGCAAATTCTTCTG-3´ 
•  wild-type (anti-sense) primer 5 -´GGCATACAGCAAATTCTTCTT-3´
 
Two internal control primers amplifying a human growth 
hormone sequence were also included in each reaction to 
confirm successful PCR amplification.
•  control (sense) primer 1: 5’ GCCTTCCCAACCATTCCCTT 3’ 
•  control (anti-sense) primer 2: 5’ TCACGGGATTTCTGTTGTGTTTC 3’
 
PCR mix, cycling conditions and resolution of products were 
standardised, as previously described.14 DNA from a known 
homozygous and heterozygous carrier of the mutation were 
amplified together with all patient samples to check for accuracy 
and consistency of the genotyping by SSP-PCR. Validation of 
the procedure was completed by sequencing five of the control 
DNA samples, together with DNA from a known homozygote 
and heterozygote for the IFNGR1 mutation, to confirm that 
genotyping by PCR-SSP was correct.
 
Results
DNA was obtained from a total of 167 patients with a past 
history of intracellular infection and from 450 anonymised 
neonatal samples obtained from cord blood samples taken 
for the purposes of routine newborn screening. The type of 
intracellular infection and method used to confirm the diagnosis 
are summarised in Table 1. 
Screening of DNA from all cases and controls using sequence 
specific primers (PCR-SSP) capable of distinguishing between 
the wild type and mutant sequence14-16 revealed no carriers for 
the IFNGR1 A>C 395 mutation in both cases and controls.
Discussion 
Newport et al in their original description of the IFNGR1 
gene defect in 1996,1 detailed the clinical and functional 
phenotype of the affected children and their heterozygous, first 
degree relatives. To date, Although this particular mutation has 
not been reported in other populations outside Malta, since the 
initial report a large body of literature has reported numerous 
other mutations in both the IFNGR1 gene and other genes 
involved in Mendelian Susceptibility to Mycobacterial Disease 
(MSMD). The clinical features of a large worldwide cohort of 
patients with recessive and dominant IFNGR1 mutation are 
well described by Dorman in 2004,18 together with the range 
of infecting pathogens. There is little doubt that, although rare, 
these conditions result in significant susceptibility to serious 
infections that may have severe clinical repercussions. Hence, 
this study addressed the question of whether the IFNGR1 gene 
mutation, described in a small group of consanguineous families 
from the island of Malta, was prevalent amongst patients from 
within the same population with a past history of intracellular 
infection. We hypothesised that an increased rate of carriage of 
the mutation would be found amongst patients with a history 
of intracellular infection. However, amongst the 167 patients 
screened, no heterozygotes were identified. Screening 450 
healthy newborns for carriage of the mutation also failed to 
identify any heterozygotes. Although our hypothesis is not 
disproved, this finding suggests that the IFNGR1 A>C 395 
mutation is very unlikely to be a significant contributor to 
intracellular infection in this island population and, therefore, 
has little or no public health significance.
Table 1: Cases of intracellular infection 
in study population
Intracellular 
infection
Disease 
type Number
Diagnostic 
criteria
Brucellosis NA 60 Serology
Leishmaniasis Visceral 27 Bone  
marrow 
aspirate
Leprosy Leproma-
tous
44 Clinical 
+/- slit skin 
smear
Tuberculosis PTB 32 21 (66%)  
culture 
proven
EPTB 4 1 (25%) cul-
ture proven
Legend: Details of past history of patients recruited to the study 
categorised by intracellular infection, together with disease type and 
method used to confirm diagnosis. (NA: not applicable, PTB: pulmonary 
TB, EPTB: extra-pulmonary TB).
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One limitation of our study is that the numbers of both 
healthy controls and patients screened was small. However, the 
study was adequately powered and suggests that the mutation, 
if present in the population, is at a prevalence of less than 0.5%. 
Furthermore, we only looked for the presence of one mutation 
within the IFNGR1 gene and it is possible that mutations 
in other regions of the gene may account for the high rates 
of susceptibility to intracellular infection. To-date however, 
the range of pathogens associated with IFNGR1 mutations 
is small,18 and these patients appear to be resistant to a wide 
range of ubiquitous bacteria, fungi, and parasites. Affected 
patients with IFNGR1 deficiency are likely to present with 
mycobacterial infections, especially those of low virulence, and 
occasionally with infections caused by non-typhoid salmonella, 
H. capsulatum, L. monocytogenes, human herpesvirus 8 and 
cytomegalovirus. 
Finally, we did not screen for other mutations in the IL-
12/IFNγ pathway. For example, both IL12RB1 and IL12p40 
deficient children and adults tend to present with infections 
caused by weakly virulent salmonella or mycobacteria that are 
usually associated with a favourable outcome.19 Some individuals 
may be completely asymptomatic whilst three patients with 
IL12RB1 deficiency have developed clinical TB20 raising the real 
possibility that defects in this gene may account for susceptibility 
to TB in the general population and possibly infection with other 
intracellular pathogens. Further screening of the population for 
defects in these genes is, therefore, warranted.
Although the island has a universal BCG vaccination 
programme administered at the age of 12 years, brucellosis, 
leishmaniasis and TB are all still prevalent and it is likely that 
any affected homozygotes would present with infection caused 
by poorly virulent mycobacteria.18 However, to-date, no further 
homozygous cases for the IFNGR1 mutation have been described 
in Malta. Thus, the original finding of the mutation amongst 
three families, all of whom originated from one town on the 
island of Malta, is likely to have been an isolated occurrence 
restricted to a small group of consanguineous families and does 
not pose a significant public health problem.
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